Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**5-fluorouracil + folinic acid** is a combination chemotherapy regimen primarily used in the treatment of colorectal cancer and other gastrointestinal cancers. 5-fluorouracil (also known as 5FU) is a pyrimidine analog that inhibits thymidylate synthase, thereby disrupting DNA synthesis and leading to cell death in rapidly dividing cells. Folinic acid (also called leucovorin or calcium folinate) is not itself a chemotherapy agent but enhances the cytotoxic effect of 5-fluorouracil by stabilizing the binding of its active metabolite (5-FdUMP) to thymidylate synthase, increasing inhibition of DNA synthesis[1][4][6]. This combination improves response rates and survival outcomes compared to using 5-fluorouracil alone[8]. The regimen is often administered intravenously.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5-fluorouracil + folinic acid.